HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

36 MONTH NON HODGKIN LYMPHOMA (NHL) CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copies of previous CRFs when completing this 36 month CRF: please complete any additional treatment details that were not captured at 24 months (for example, additional treatments, or end dates of those ongoing in earlier CRFs)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID	/	/				
Participant's date of birth	d d	m m	У	У	У	У

Has the participant developed any NEW co-morbidities (which were not recorded in any previous CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrhythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	
Clinical diagnosis of depression	
Other psychiatric diagnosis (e.g. schizophrenia, bipolar disorder etc.)	

Participant's Study ID			
------------------------	--	--	--

Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	
Other (please give details)	
Other (please give details)	

Participant's Study ID		/		/			

What treatments has the participant received **since those captured in any previous CRFs**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing previously (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has received	Start date of treatment (dd/mm/yyyy)	End date of treatment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Combination Chemothera-	СНОР		//20	//20	
ру	ICE		//20	//20	
	DHAP		//20	//20	
	Gemcitabine and Cisplatin		//20	//20	
	Other (please describe)		//20	//20	
	Other (please describe)		//20	//20	
	Chemotherapy number of cycles, please enter on line				
	If there were any amendments to chemotherapy dose during treatment, please give a reason				
Monoclonal Antibody	Rituximab		//20	//20	
	Other (please state)		//20	//20	
	Monoclonal antibody number of cycles,	please ente	er on line		
Stem Cell Transplant	Autologous transplant/High dose therapy and stem cell support		// 20	// 20	
	Allogenic transplant		//20	//20	

Participa	nt's Study ID /	/			
Treatment type	Specific treatment details	Tick if patient has re- ceived	Start date of treatment (dd/mm/yyyy)	End date of treatment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a
Radiotherapy	Radiotherapy		// 20	//20	
	Reason for radiotherapy (e.g. consolidation	n or disease	relapse), please e	nter on line	
	Total radiotherapy dose, please enter on I				
	Number of radiotherapy fractions, please				
	Radiotherapy site, please enter on line				
Additional Treatment	If any additional treatment has been given please describe		//20	// 20	
Were any o	of the treatments detailed above	e given v	vith palliative	e intent?	
(please tick	one box) Yes	No	Uı	nknown	
If yes, pleas	se indicate which treatments?				

Participant's Study ID / /	
Has the participant had a relapse (or further relapse) of their non-Hodgkin ly (please tick one box)	mphoma?
Yes No Unknown	
If the participant has had a relapse, on what date was the relapse diagnosed	?
d d m m y y y y	
If the participant has had a relapse, was the relapse at the original site or at a (please tick one box)	a new site?
Original site	
New site	
Has the participant's lymphoma become refractory (failure to respond/resist treatment)? (please tick one box)	ance to
Yes No Unknown	

Participant's Study ID /	
Is the participant taking part in a clinical to	rial? (please tick one box)
Yes No	Unknown
If you answered "yes" to the above questic trial the participant is taking part in	on, please give the NAME of the clinical
Name of clinical trial	
Since the participant's diagnosis of non-Howith another new primary cancer? (please Yes No	dgkin lymphoma, have they been diagnosed tick one box) Unknown
If you answered "yes" to the above questi about the participant's new cancer diagno	
Type of cancer	
Date of diagnosis	// 20
Treatment received	
Date treatment ended (if finished)	// 20

Participant's Study ID / / /	
What type of follow-up care is the participant receiving? (please tick ONE box	()
Routine/regular hospital clinic based follow-up (medical or nurse led, face-to-face or by telephone)	
Primary care based follow-up	
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)	
If the participant is receiving patient-initiated follow-up, on what date were	
they discharged to this?	
Has the participant been referred to any of the following services and/or had	la

Participant has been referred to palliative care services

If available, please give reason for referral (e.g. end of life care, symptom management)

Participant has been referred to psychological services

If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)

Participant has been referred to community services

Participant has been referred for treatment related problems (e.g. pain clinic)

If ticked, please provide more details below:

Participant has had an HNA (holistic needs assessment)

Participant's Study ID / /
If the participant has died please give the date and cause of death: Participant's date of death
Cause of participant's death
1) a)
1) b)
1) c)
2)
Cause of death not known
Please add your name and signature and the date that you completed this CRF
Name Signature
Date CRF completed dd / m m / y y y y